Dialysis Access Interventions Research Articles

Practice of dialysis access interventional nephrology procedures in the Asia-Pacific region: Getting lay of the land.

This cross-sectional survey aimed to determine the prevalence of Interventional Nephrology (IN) practice amongst nephrologists in the Asia-Pacific Region (APR), specifically related to dialysis access (DA). The Association of VA and intervenTionAl Renal physicians (AVATAR) Foundation from India conducted a multinational online survey amongst nephrologists from the Asia-Pacific to determine the practice of IN in the planning, creation, and management of dialysis access. The treatment modalities, manpower and equipment availability, monthly cost of treatment, specifics of dialysis access interventions, and challenges in the training and practice of IN by nephrologists were included in the survey. Twenty-one countries from the APR participated in the survey. Nephrologists from 18 (85.7%) countries reported performing at least one of the basic dialysis access-related IN procedures, primarily the placement of non-tunnelled central catheters (n-TCC; 71.5%). Only 10 countries (47.6%) reported having an average of <4% of nephrologists performing any of the advanced IN access procedures, the most common being the placement of a peritoneal dialysis (PD) catheter (20%). Lack of formal training (57.14%), time (42.8%), incentive (38%), institutional support (38%), medico-legal protection (28.6%), and prohibitive cost (23.8%) were the main challenges to practice IN. The primary obstacles to implementing the IN training were a lack of funding and skilled personnel. The practice of dialysis access-related IN in APR is inadequate, mostly due to a lack of training, backup support, and economic constraints, whereas training in access-related IN is constrained by a lack of a skilled workforce and finances.

Role of stenting for maintenance of the extremity fistula/graft overview.

Dialysis access interventions have undergone significant developments over the last few decades. Angioplasty has been the mainstay of therapy since the early interventions in the 1980s and 1990s, but poor long-term patency and early loss of access has led investigators to assess other devices to treat stenoses associated with dialysis access failure. Multiple retrospective studies of stents for treatment of stenoses that did not respond to angioplasty demonstrated that the long-term outcomes were not improved over angioplasty alone. Cutting balloons have been studied in a prospective randomized fashion but also showed no long-term improvement over angioplasty alone. Prospective randomized trials have demonstrated that stent-grafts have superior primary patency of the access and the target lesions than angioplasty. The purpose of this review is to summarize the current state of knowledge regarding stent and stent graft use in dialysis access failure. We will discuss the early observational data related to stent use in dialysis access failure including the earliest reports of stent use in dialysis access failure. This review will then focus the review on the prospective randomized data that supports the use of stent-grafts in specific areas of access failure. These include venous outflow stenosis related to grafts, cephalic arch stenoses, native fistula intervention, and the use of stent-grafts to revise in-stent restenosis. Each of these applications will be summarized and the current status of the data will be reviewed.

Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease.

Anaemia occurs in chronic kidney disease (CKD) and is more prevalent with lower levels of kidney function. Anaemia in CKD is associated with death related to cardiovascular (CV) disease and infection. Established treatments include erythropoiesis-stimulating agents (ESAs), iron supplementation and blood transfusions. Oral hypoxia-inducible factors (HIF) stabilisers are now available to manage anaemia in people with CKD. We aimed to assess the benefits and potential harms of HIF stabilisers for the management of anaemia in people with CKD. We searched the Cochrane Kidney and Transplant Register of Studies up to 22 November 2021 through contact with the Information Specialist using search terms relevant to our review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal, and ClinicalTrials.gov. Randomised and quasi-randomised studies evaluating hypoxia-inducible factors stabilisers compared to placebo, standard care, ESAs or iron supplementation in people with CKD were included. Five authors independently extracted data and assessed the risk of bias. Treatment estimates were summarised using random effects pair-wise meta-analysis and expressed as a relative risk (RR) or mean difference (MD), with a corresponding 95% confidence interval (CI). Evidence certainty was assessed using GRADE. We included 51 studies randomising 30,994 adults. These studies compared HIF stabilisers to either placebo or an ESA. Compared to placebo, HIF stabiliser therapy had uncertain effects on CV death (10 studies, 1114 participants): RR 3.68, 95% CI 0.19 to 70.21; very low certainty evidence), and nonfatal myocardial infarction (MI) (3 studies, 822 participants): RR 1.29, 95% CI 0.31 to 5.36; I² = 0%; very low certainty evidence), probably decreases the proportion of patients requiring blood transfusion (8 studies, 4329 participants): RR 0.51, 95% CI 0.44 to 0.60; I² = 0%; moderate certainty evidence), and increases the proportion of patients reaching the target haemoglobin (Hb) (10 studies, 5102 participants): RR 8.36, 95% CI 6.42 to 10.89; I² = 37%; moderate certainty evidence). Compared to ESAs, HIF stabiliser therapy may make little or no difference to CV death (17 studies, 10,340 participants): RR 1.05, 95% CI 0.88 to 1.26; I² = 0%; low certainty evidence), nonfatal MI (7 studies, 7765 participants): RR 0.91, 95% CI 0.76 to 1.10; I² = 0%; low certainty evidence), and nonfatal stroke (5 studies, 7285 participants): RR 1.06, 95% CI 0.71 to 1.56; I² = 8%; low certainty evidence), and had uncertain effects on fatigue (2 studies, 3471 participants): RR 0.80, 95% CI 0.56 to 1.16; I² = 0%; very low certainty evidence). HIF stabiliser therapy probably decreased the proportion of patients requiring blood transfusion (11 studies, 10,786 participants): RR 0.87, 95% CI 0.76 to 1.00; I² = 25%; moderate certainty evidence), but may make little or no difference on the proportion of patients reaching the target Hb (14 studies, 4601 participants): RR 1.00, 95% CI 0.93 to 1.07; I² = 70%; low certainty evidence), compared to ESA. The effect of HIF stabilisers on hospitalisation for heart failure, peripheral arterial events, loss of unassisted dialysis vascular access patency, access intervention, cancer, infection, pulmonary hypertension and diabetic nephropathy was uncertain. None of the included studies reported life participation. Adverse events were rarely and inconsistently reported. HIF stabiliser management of anaemia had uncertain effects on CV death, fatigue, death (any cause), CV outcomes, and kidney failure compared to placebo or ESAs. Compared to placebo or ESAs, HIF stabiliser management of anaemia probably decreased the proportion of patients requiring blood transfusions, and probably increased the proportion of patients reaching the target Hb when compared to placebo.

Effectiveness and safety of repeated percutaneous intervention in an office-based endovascular center in maintaining hemodialysis access.

Percutaneous dialysis access interventions are routinely used to maintain the patency of dialysis access despite the lack of data regarding their long-term effectiveness. This retrospective study was undertaken to study the effectiveness and safety of percutaneous dialysis access interventions in arm fistulas and bridge grafts in an office-based endovascular center. Patients who had a percutaneous dialysis access intervention in their upper extremity access site, performed at a single office-based endovascular center over a nine-year period (2007-2016) were included in this study. The patients' demographic factors, patency, and complications were analyzed. Patients were entered in the study after first percutaneous dialysis access intervention. A total of 298 limbs in 259 patients had 913 procedures carried out over a nine-year period. There were 190 access arteriovenous fistulas and 108 arteriovenous grafts. The two most common arteriovenous fistulas were the brachiocephalic fistula (n = 74, 39%) and radio cephalic fistula (n = 69, 36%). Arteriovenous grafts were most commonly placed in the upper arm (n = 66, 61%) followed by the forearm (n = 42, 39%). The mean overall patency for all limbs was 50.86 months. Arteriovenous fistulas had a significantly longer patency than arteriovenous grafts (51.65 vs. 42.09 months; P = 0.01). In addition, patients with two or more percutaneous dialysis access intervention in their arteriovenous fistula had significantly greater patency than those with only one percutaneous dialysis access intervention (58.5 vs. 7.6 months; hazard ratio 0.41; P = 0.0008). This was not true for the arteriovenous graft group. Women represented 49% of the patient group. Their accesses had shorter patency than men (39.8 vs. 60 months; P = 0.0007). This data support the use of repeated percutaneous dialysis access intervention to maintain long-term patency of dialysis access sites in an office-based endovascular center. Overall, fistulas have longer patency than grafts and women have poorer outcomes as compared to men.

The usefulness and feasibility of placing a clinch knot with a guidewire to achieve temporary hemostasis in arteriovenous dialysis access interventions.

To evaluate the usefulness and feasibility of using a reversible clinch knot with a guidewire in place rather than eliminating the access route during an arteriovenous hemodialysis access (AV access) intervention using the facing sheath technique. From July 2016 to June 2019, we retrospectively studied 78 sessions performed as interventional treatment for arteriovenous (AV) hemodialysis (HD) access using the "facing-sheath technique." In all sessions, all antegrade sheaths were removed while a 0.035-inch guidewire remained in place with purse-string suture and the clinch knot. Seventy-two sessions were performed in patients with thrombosed AV accesses (69 arteriovenous grafts [AVGs] and three arteriovenous fistulas [AVFs]), and six sessions were carried out to treat non-thrombosed AV accesses (four AVGs and two AVFs). We evaluated whether proper hemostasis and successful reinsertion of the sheath over the wire into the clinch knot was achieved. Clinical success was defined as achieving prompt restoration of blood flow for AV access, and the postintervention primary and secondary patency were also evaluated. In all 87 clinch knots created in 78 total sessions, proper hemostasis was achieved. All clinch knots that required reversal for additional procedures were successfully reopened (55 clinch knots in 50 sessions). The postintervention primary patency rates at 1, 3, and 6 months, and at 1 year were 77.8%, 68.9%, 55.6%, and 33.3%, respectively. The postintervention secondary patency rates at 1, 3, and 6 months, and also at 1 year were 93.3%, 91.1%, 86.7%, and 86.7%, respectively. Our AV access intervention which used a clinch knot with purse-string suture while the guidewire remained in place was both useful and feasible for maintaining temporary hemostasis.

Misalignment between reimbursement and clinical guidelines for dialysis access intervention is unlikely to improve quality or efficiency of patient care

In their article, Madden et al1 have appropriately focused our attention on recent changes in reimbursement for specific procedures used to prolong the lifespan of dialysis arteriovenous fistulae and grafts. In a constantly shifting effort to drive care for these patients to more cost-efficient venues, the Centers for Medicare and Medicaid Services (CMS) reimbursement has resulted in the proliferation of outpatient vascular access centers across the country. The positive aspects of this shift include avoidance of high hospital-based facility fees, preservation of high-capability hospital-based facilities for patients who need to be treated in these facilities, and potentially increasing patient satisfaction in a specialized facility that can expeditiously manage access complications with a team specifically designed for this purpose.

Intravascular ultrasound imaging for the optimization of dialysis access interventions.

Intravascular ultrasound allows for detailed imaging of the dialysis access anatomy. Accurate visualization and precise measurements of the anatomy can be obtained using intravascular ultrasound, while limiting contrast usage and radiation exposure. Intravascular ultrasound allows for a true appreciation of stenosis morphology and can further guide endovascular management decisions, with a particular benefit in management of central venous lesions. Here, we describe a series of cases that together highlight the advantages of using intravascular ultrasound in the evaluation and management of dialysis access care.

Fistuloplasty using a radiation-and-time-saving sheathless balloon catheter

Introduction:Sheath placement in dialysis access interventions is traditionally necessary to obtain imaging, guide percutaneous angioplasty, and evaluate results. The aim of this study was to assess the feasibility of performing sheathless Arterio-venous (AV) access interventions using a novel percutaneous angioplasty balloon catheter.Methods:Between May and September 2017, data on all dialysis access interventions using a novel percutaneous angioplasty balloon with a dedicated injection port were collected. All procedures were performed without a sheath. Success was established as no conversion to sheath placement. Demographic data, location of lesion, time to perform procedure, amount of contrast used, radiation exposure, and access complications were recorded. Ultrasound was used to evaluate access site complications.Results:Sheathless interventions were successful in 24 patients with the mean age of 62 years (29–94). There were 5 PTFE grafts and 19 native fistulas. Lesions were located anywhere from the arterial anastomosis to the cephalic arch. The average balloon size was 6 mm (5–7 mm), and the procedure time was 15.8 min (8–45 min). No access site complications were observed.Conclusion:Sheathless intervention is feasible with several potential advantages, including short procedure time, minimal contrast volume, and reduced radiation exposure. Finally, the lower profile at the access site may result in fewer complications.

Omega-3 Polyunsaturated Fatty Acid Supplementation to Prevent Arteriovenous Fistula and Graft Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Arteriovenous access failure frequently occurs in people on hemodialysis and is associated with morbidity, mortality and large healthcare expenditures. Omega-3 polyunsaturated fatty acids (omega-3 PUFA) may improve access outcomes via pleiotropic effects on access maturation and function, but may cause bleeding complications. Systematic review with meta-analysis. Adults requiring hemodialysis via arteriovenous fistula or graft. Trials evaluating omega-3 PUFA for arteriovenous access outcomes identified by searches in CENTRAL, MEDLINE, and Embase to 24 January 2017. Omega-3 PUFA. Primary patency loss, dialysis suitability failure, access abandonment, interventions to maintain patency or assist maturation, bleeding, gastrointestinal side-effects, all-cause and cardiovascular mortality, hospitalization, and treatment adherence. Treatment effects were summarized as relative risks (RR) and 95% confidence intervals (CI). Evidence was assessed using GRADE. Five eligible trials (833 participants) with a median follow-up of 12 months compared peri-operative omega-3 PUFA supplementation with placebo. One trial (n=567) evaluated treatment for fistulae and four (n=266) for grafts. Omega-3 PUFA supplementation prevented primary patency loss with moderate certainty (761 participants, RR 0.81, CI 0.68-0.98). Low quality evidence suggested, that omega-3 PUFA may have had little or no effect on dialysis suitability failure (536 participants, RR 0.95, CI 0.73-1.23), access abandonment (732 participants, RR 0.78, CI 0.59-1.03), need for interventions (732 participants, RR 0.82, CI 0.64-1.04), or all-cause mortality (799 participants, RR 0.99, CI 0.51-1.92). Bleeding risk (793 participants, RR 1.40, CI 0.78-2.49) or gastrointestinal side-effects (816 participants, RR 1.22, CI 0.64-2.34) from treatment were uncertain. There was no evidence of different treatment effects for grafts and fistulae. Small number and methodological limitations of included trials. Omega-3 PUFA supplementation probably protects against primary loss of arteriovenous access patency, but may have little or no effect on dialysis suitability failure, access interventions or access abandonment. Potential treatment harms are uncertain.

Management of hypertension in patients during percutaneous dialysis access interventions.

Not infrequently, interventionalists are faced with a patient with increased blood pressure who is about to undergo a dialysis access intervention such as tunneled hemodialysis catheter, percutaneous balloon angioplasty, or declotting procedure for a clotted arteriovenous access. This can frequently create a dilemma as functional dialysis access is needed to provide dialysis therapy and delaying treatment could result in a life-threatening situation, particularly in the presence of hyperkalemia. This article investigates hypertension in patients undergoing percutaneous dialysis access interventions and provides guidance to their management.

Treatment outcomes and lessons learned from 5134 cases of outpatient office-based endovascular procedures in a vascular surgical practice.

Introduction The office-based endovascular facility has increased in number recently due in part to expedient patient experience. This study analyzed treatment outcomes of procedures performed in our office-based endovascular suite. Methods Treatment outcomes of 5134 consecutive procedures performed in our office-based endovascular suites from 2006 to 2013 were analyzed. Five sequential groups (group I-V) of 1000 consecutive interventions were compared with regard to technical success and treatment outcomes. Results Our patients included 2856 (56%) females and 2267 (44%) males. Procedures performed included diagnostic arteriogram, arterial interventions, venous interventions, dialysis access interventions, and venous catheter management, which were 1024 (19.9%), 1568 (30.6%), and 3073 (60.0%), 621(12.1%), and 354 (6.9%), respectively. The complication rates for group I, II, III, IV, and V were 3%, 1.5%, 1%, 1.1%, and 0.7%, respectively. The complication rate was higher in group I when compared to each of the remaining four groups ( p < 0.05). Nine patients (0.18%) died within the 30-day period following their procedures, and none were procedure related. Conclusions Endovascular procedure can be performed safely in an office-based facility with excellent outcomes. Lessons learned in establishing office-based endovascular suites with efforts to reduce procedural complications and optimize quality patient care are discussed.

The next frontier of office-based inferior vena cava filter placement.

There is an increasing number of procedures that traditionally were performed in the inpatient setting that arenow becoming office-based procedures. These include peripheral endovascular procedures such as angiograms, angioplasties, dialysis access interventions, and treatment for venous insufficiency. We chose to evaluate the feasibility, safety of inferior vena cava (IVC) filter placement in the office-based setting. All procedures were performed using local anesthesia, and ultrasound guidance for puncture. All venograms were performed with manual injection of iodinated contrast. An IVC filter was placed in the cases (except one failure of placement) using fluoroscopy in the infrarenal position. Patients were observed in a recovery area and then discharged. Follow-up data were obtained through an interview, physical examination, and 24-hour postoperative phone call. Over the course of 27months, 29 Greenfield filters (Boston Scientific, Marlborough, Mass) and three Celect temporary filters (Cook, Bloomington, Ind) were placed in the infrarenal IVC for 18 women and 14 men, with an average age of 75.3± 15.6years (range, 38-97years). Twenty-four acute, 6 recent (<6months ago) and three subacute lower extremity deep vein thromboses (DVTs) wereidentified. The indications for the procedure were patients with: DVT who were to undergo surgery (n= 6),acute large free-floating iliofemoral DVT (deemed high-risk for long-term anticoagulation) (n=7), new DVTduring anticoagulation therapy (n= 6), DVT with gastrointestinal bleeding (n= 4), DVT withhematuria (n= 2), recent DVT (which extended during fulldose anticoagulation treatment) while undergoing a longflight (n= 1) (temporary filter placement), DVTwith arm hematoma (n= 1), DVT with unsteady gaitand history offalls (n= 2), DVT with nose bleeding(n= 1), DVT withdementia and inability to receive anticoagulation treatment (n= 1), DVT and receiving chemotherapy and withthrombocytopenia (n= 1), and DVT and refusal to takeanticoagulation medication(n= 1). One patient had afailure to place a filterbecause of chronic IVC occlusion found on venogram.One patient with history of gastrointestinal bleeding,acute DVT, and atrial fibrillation suffered IVC filterthrombosis 1month after the procedure. We attemptedremoval of the temporary filters in the hospital in two patients but failed to retrieve the filter in thesetwo cases.We noted no insertion site DVT, extension ofDVT, orpulmonary embolism. Our preliminary experience suggests that placement of IVC filters for treatment of venous thrombotic eventsin an office-based facility is safe and efficacious with basic endovascular equipment. Long-term outcome cannot be determined at this point.

Dialysis Access Anatomy and Interventions: A Primer.

The creation of arteriovenous fistulae and the use of arteriovenous grafts are a vital component in the treatment of patients undergoing dialysis. For many patients in this population, these accesses represent the permanent solution to their dialysis needs. Understanding the basic anatomy of the most common accesses used, as well as initial treatment of many underlying causes of access failure is vital for any interventionalist performing such procedures. This article outlines the most common approaches to surgically placed accesses used for renal replacement therapy, as well as the basics of interventional approaches used to treat the most common abnormalities causing their dysfunction.

Important Contributions to the Interventional Radiology Dialysis Literature, 2014-2015.

Dialysis access interventions remain a vital component of long-term care for the dialysis population. Several advances have been published in the past two years, including both advances in the creation of accesses as well as treatment of specific processes leading to dialysis access failures. Advances in tools and other techniques used in dialysis access maintenance have also led to significant improvements in outcomes in this patient population. The purpose of this article is to provide synopses of some of the most important literature published in 2014-2015, and to provide objective data for the reader to make their own decisions regarding interventions performed in this patient population.

Educational ExhibitAbstract No. 507 - Transjugular approach for upper extremity AV dialysis access interventions

Educational ExhibitAbstract No. 507 - Transjugular approach for upper extremity AV dialysis access interventions

Office-Based IVC Filter Placement: The Next Frontier

An increasing number of procedures that traditionally were performed in the inpatient setting are now becoming office-based procedures. These include peripheral endovascular procedures such as angiograms, angioplasties, dialysis-access interventions, and venous insufficiency treatments. These have been performed in the office with minimal complications. We chose to evaluate the feasibility, safety of inferior vena cava (IVC) filter placement in the office-based setting. All procedures were performed under local anesthesia and using ultrasound guidance for puncture. All venograms were performed with hand injection of dye. An IVC filter was placed in the cases (except one failure of placement) under fluoroscopy at the level of L2-L3 in the infrarenal position. Patients were observed in a recovery area and discharged to home. Follow-up data were obtained through an interview, physical examination, and 24-hour postoperative phone call. At 1 week, duplex of the IVC filter and the puncture site was performed. At the 3-month follow-up, a venous and IVC duplex scan was performed. Over the course of 27 months, 29 Greenfield filters and 3 Celect temporary filters were placed in infrarenal IVC for 18 women and 14 men, with average age of 76.1 years (range, 38-97; standard deviation, ±15.1 years). Failure to place a filter occurred in one patient due to chronic IVC occlusion. The indications for the procedure were acute free-floating DVT in 10, contraindication to anticoagulation in 13, failure of anticoagulation in 5, high-risk patients in 2, patient-related contraindication such as dementia in 2, and refusal to be anticoagulated in 1. One 89-year-old patient had IVC filter thrombosis 2 months after placement of the IVC filter. The remainder of patients did not experience any complications, including but not limited to infection, bleeding, filter thrombosis, insertion-site thrombosis, perforation of the vena cava, recurrent pulmonary embolism, admission to the hospital, and death, within 24 hours (n = 32), 1 week (n = 32), and 3 months (n = 25) of follow-up time. Our preliminary experience suggests that placement of IVC filters for treatment of venous thrombotic events in an office-based facility is safe and efficacious with basic endovascular equipment. The long-term outcome cannot be determined at this point.

Thrombocytopenia in ESRD Patients: Epidemiology, Mechanisms and Interventional Nephrology Perspective

A well-functioning vascular access is essential for provision of life-sustaining dialysis treatment in patients with end-stage renal disease. Arteriovenous accesses are preferred form of vascular access. Although significant advances have been made in the field of dialysis access, arteriovenous access dysfunction remains the single most important cause of morbidity in ESRD patients. While thrombosis and stenosis of AV access are more frequently seen, hemorrhage from AV access can be life threatening with or without risk of permanent access loss. Aside from anticoagulation for comorbidities, qualitative and/or quantitative platelet abnormalities are often the predisposing factors. We describe an ESRD patient who developed new onset but severe thrombocytopenia due to metastatic small cell neuroendocrine carcinoma of lung. Given her persistent thrombocytopenia and presence of prolonged bleeding from the cannulation sites, a right internal jugular tunneled dialysis catheter was placed for continuation of maintenance dialysis. This review discusses the definition of thrombocytopenia, mechanisms of thrombocytopenia in patients with ESRD and with a special focus on implications of thrombocytopenia on dialysis access interventions. The review underscores the need for consensus with regard to cannulating AV access as well as guidelines specific to dialysis access-related endovascular intervention in the setting of thrombocytopenia and other coagulation abnormalities.

Blood Pressure Recordings During Hemodialysis Access Interventions: Implications for Acute Management

A retrospective study evaluating the pattern of blood pressure and its related complications before, during, and after percutaneous hemodialysis interventions was performed in patients presenting with asymptomatic hypertension. Hemodialysis patients undergoing percutaneous interventions including tunneled hemodialysis catheter insertion, percutaneous balloon angioplasty and thrombectomy procedure, and stage II hypertension (systolic blood pressure ≥160 mmHg) were included in this analysis. Blood pressure medications were not used while midazolam and fentanyl were routinely administered. Patients were followed for up to 4 weeks to monitor any complications. The mean blood pressure before, during, and after the procedures were 185 ± 18/96 ± 14, 172 ± 22/92 ± 15, and 153 ± 25/87 ± 14, respectively. There was a statistically significant difference between the blood pressure readings before and after the procedure (before = 185 ± 18/96 ± 14, after = 153 ± 25/87 ± 14; p = 0.001). None of the patients had a stroke, myocardial infarction, or acute pulmonary edema before, during, or after the procedure or during the 4-week follow-up period. A significant reduction in blood pressure was observed after the procedure without the administration of any antihypertensive medication. These results suggest that the reduction in blood pressure observed after percutaneous dialysis access interventions (particularly in the presence of midazolam and fentanyl) may make it unnecessary to treat asymptomatic hypertension prior to these procedures.

Abstract No. 453: Strategies for pre-procedure and intra-procedural doppler ultrasound in dialysis access interventions

Abstract No. 453: Strategies for pre-procedure and intra-procedural doppler ultrasound in dialysis access interventions

Abstract No. 95: Direct intra-access flow measurement as a problem solving tool in hemodialysis access interventions

The technical success of percutaneous dialysis access interventions can usually be determined by physical examination (PE). However, when a discrepancy exists between PE and angiographic findings, we believe that intra-access direct flow measurements offer supplemental information, and thus may be used as a problem solving tool or to gain additional information about the access. The purpose of this study was to identify procedural scenarios in which flow measurements were made and how they affected the chosen course of action.